ImmunoGen News

ImmunoGen, Inc. , a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload antibody-drug conjugate technology, today announced that Gregory Perry, Executive Vice President and Chief Financial Officer, will present at the upcoming Credit Suisse Antibody Day in New York.

ImmunoGen issued its quarterly earnings data on Friday. The company reported earnings per share for the quarter, beating the analysts' consensus estimate of by $0.13, Analyst Ratings.Net reports.

"Based on published clinical findings and patient anecdotes, we believe Kadcyla will make a notable difference for many patients and become a highly successful product," commented Daniel Junius, President and CEO.

The firm currently has a "hold" rating on the stock. Several other analysts have also recently commented on the stock.

ImmunoGen, Inc. , a biotechnology company that develops targeted anticancer therapeutics, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 26, 2013, to discuss ImmunoGen's financial results for the three-month period ended March 31, 2013 - the third quarter of the Company's 2013 fiscal year.